Modongo C, Wang Q, Dima M, et al. - In view of the recent recommendation of Dolutegravir (DTG) as a preferred first-line regimen for the treatment of new and treatment-experienced HIV-infected cases, researchers here focussed on potential drug interactions between DTG and rifampicin, which remain a clinical and public health concern. HIV-infected cases who were concomitantly receiving rifampicin- and DTG-based regimens under programmatic conditions in Botswana were analyzed for their HIV and tuberculosis (TB) treatment outcomes. In the analysis, a total of 1,225 cases were included. Outcomes revealed the achievement of favorable TB and HIV treatment outcomes in correlation to using DTG-based antiretroviral therapy (ART) regimens in cases coinfected with TB and HIV; these outcomes were comparable to those achieved with alternative ART regimens. Results are thereby reassuring to TB and HIV programs concerning the overall programmatic simultaneous use of these first-line treatment regimens for the management of HIV and TB coinfected cases.